CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study arm used a Rybelsus(R) composition processed with DehydraTECH that is compliant with the FDA’s Inactive Ingredient Database (“FDA IID”), delivered within an in-mouth dissolvable tablet. According to the announcement, this will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can absorb at any level systemically through the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective drug delivery into…